SM
BRTX icon

Sabby Management’s BioRestorative Therapies BRTX Stock Holding History

Sabby Management’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-168,544
Closed -$233K – 45
2024
Q1 		$233K Buy
+168,544
New +$260K 0.13% 21
2022
Q1 		– Sell
-10,000
Closed -$43K – 157
2021
Q4 		$43K Buy
+10,000
New +$57.1K 0.01% 171

Other funds holding BRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UFA
US Financial Advisors Braintree, Massachusetts $338M AUM 4.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Sabby Management's BRTX Position: Q2 2024 in Review

Sabby Management sold out of BioRestorative Therapies (BRTX) in Q2 2024, closing a stake of 168,544 shares — an estimated $233K sold.

Sabby Management first reported a position in BRTX in Q4 2021 and held it in 2 quarters. The position peaked at $233K in Q1 2024. 12 funds tracked by Wall St. Rank hold BRTX as of Q2 2024.

  • Sabby Management reported no remaining BioRestorative Therapies position as of Q2 2024 after selling out during the quarter.
  • Sabby Management sold 168,544 BioRestorative Therapies shares in Q2 2024, an estimated $233K.
  • Sabby Management first reported a position in BioRestorative Therapies in Q4 2021 and held it in 2 quarters.
  • Sabby Management's BioRestorative Therapies position peaked at $233K in Q1 2024.
  • 12 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2024.

Based on Sabby Management's 13F filing for Q2 2024, filed 14 Aug 2024.